[Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma]

In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous symptoms associated with EV treatment. Currently, the only reported associations of EV with cutaneous symptoms are pre-treatment performance status (PS) and body weight. However, no report has focused on the association between hematological factors and cutaneous symptoms. We retrospectively examined the occurrence of cutaneous symptoms and associated factors in patients who had been treated with EV for UC at Nagasaki University Hospital between February 2022 and June 2023. We evaluated the six patients with bladder cancer and three cases of upper urinary tract cancer. The median age was 73 [57-85] years. Seven patients had cutaneous reactions with EV treatment, and the median date of onset of the cutaneous symptoms was seven　[4 -28] days. PS was better inthe group with skinsymptoms compared with the group without (median : 1.0 vs 3.0), and in those with a higher incidence of eosinophilia or cutaneous symptoms on the previous regimen (71. 4% vs 0%). We suggested that the presence of eosinophilia or cutaneous symptoms at the time of pre-EV regimen administration may be a predictor of the appearance of cutaneous symptoms at the time of EV treatment. The limitation is that it is a single-center, small-case series, which does not allow for a rigorous statistical study.